Blythman HE - Search Results

1

Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin.

Bourrie BJ, Casellas P, Blythman HE, Jansen FK. Bourrie BJ, et al. Among authors: blythman he. Eur J Biochem. 1986 Feb 17;155(1):1-10. doi: 10.1111/j.1432-1033.1986.tb09451.x. Eur J Biochem. 1986. PMID: 3948873 Free article.

2

Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients.

Laurent G, Pris J, Farcet JP, Carayon P, Blythman H, Casellas P, Poncelet P, Jansen FK. Laurent G, et al. Blood. 1986 Jun;67(6):1680-7. Blood. 1986. PMID: 3085747 Free article.

3

Present potential of immunotoxins.

Poncelet P, Blythman HE, Carriere D, Casellas P, Dussossoy D, Gros O, Gros P, Jansen FK, Laurent JC, Liance MC, et al. Poncelet P, et al. Among authors: blythman he. Behring Inst Mitt. 1984 May;(74):94-100. Behring Inst Mitt. 1984. PMID: 6383330

4

[Immunotoxins].

Jansen FK, Blythman HE, Carrière D, Casellas P, Dussossoy D, Gros O, Gros P, Laurent JC, Paolucci F, Pau B, Poncelet P, Richer G, Vidal H, Voisin GA. Jansen FK, et al. Among authors: blythman he. Bull Cancer. 1983;70(3):165-8. Bull Cancer. 1983. PMID: 6882931 French.

5

Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells.

Blythman HE, Casellas P, Gros O, Gros P, Jansen FK, Paolucci F, Pau B, Vidal H. Blythman HE, et al. Nature. 1981 Mar 12;290(5802):145-6. doi: 10.1038/290145a0. Nature. 1981. PMID: 7207595

6

Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity.

Jansen FK, Blythman HE, Carrière D, Casellas P, Gros O, Gros P, Laurent JC, Paolucci F, Pau B, Poncelet P, Richer G, Vidal H, Voisin GA. Jansen FK, et al. Among authors: blythman he. Immunol Rev. 1982;62:185-216. doi: 10.1111/j.1600-065x.1982.tb00394.x. Immunol Rev. 1982. PMID: 7042538 Review. No abstract available.

7

An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin.

Hertler AA, Schlossman DM, Borowitz MJ, Blythman HE, Casellas P, Frankel AE. Hertler AA, et al. Among authors: blythman he. Int J Cancer. 1989 Feb 15;43(2):215-9. doi: 10.1002/ijc.2910430207. Int J Cancer. 1989. PMID: 2465276

8

Thy 1.2+ leukemia cells eradicated from in vitro leukemia-bone marrow cell mixtures by antibody-toxin conjugates.

Colombatti M, Colombatti A, Blythman HE, Bron C. Colombatti M, et al. Among authors: blythman he. J Natl Cancer Inst. 1984 May;72(5):1095-9. J Natl Cancer Inst. 1984. PMID: 6585586

9

Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.

Antin JH, Bierer BE, Smith BR, Guinan EC, Provost MM, Ferrara J, Macklis RM, Tarbell NJ, Blythman H, Bouloux C, et al. Antin JH, et al. Prog Clin Biol Res. 1990;333:207-15. Prog Clin Biol Res. 1990. PMID: 1689852 No abstract available.

10

Immunotoxin therapy: assessment by animal models.

Griffin TW, Morgan AC, Blythman HE. Griffin TW, et al. Among authors: blythman he. Cancer Treat Res. 1988;37:433-55. doi: 10.1007/978-1-4613-1083-9_24. Cancer Treat Res. 1988. PMID: 2908638 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters